At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,295 enrolled
Drug / intervention
Aggrenox capsule +1 moredrug
Likely dose
Aggrenox capsule 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
In Brief
A Phase 3 clinical trial evaluating Aggrenox capsule and Acetylsalicylic Acid (ASA) for Cerebrovascular Accident. Completed, enrolled 1,295 participants across 151 sites.
Detailed Summary
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebrovascular Accident
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionMar 2009
TodayJul 2026
First PostedApr 6, 2006
Enrollment StartApr 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.2 years ago
Interventions
Aggrenox capsuledrug
extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
Acetylsalicylic Acid (ASA)other
Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily